CD209 and neoplasm: By reducing the expression of M2 macrophage markers (CD163 and CD209) and suppressing the release of tumor-promoting factors such as MMP-9, RANTES, and VEGF, Deoxyschizandrin mitigates the supportive role of TAMs in tumor progression.